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2ABSTRACT 
Hemolytic Uremic Syndrome (HUS) is an important cause of acute renal failure in 
children. Mutations in one or more genes encoding complement regulatory proteins 
have been reported in approximately one third of non-diarrheal, atypical HUS patients, 
suggesting a defect in the protection of cell surfaces against complement activation in 
susceptible individuals. Here we identified a subgroup of aHUS patients showing 
persistent activation of the complement alternative pathway and found within this 
subgroup two families with mutations in the gene encoding factor B (BF), a zymogen 
that carries the catalytic site of the complement alternative pathway convertase 
(C3bBb). Functional analyses demonstrated that F286L and K323E aHUS-associated 
BF mutations are gain-of-function mutations that result in enhanced formation of the 
C3bBb convertase or increased resistance to inactivation by complement regulators. 
These data expand our understanding of the genetic factors conferring predisposition to 
aHUS, demonstrate the critical role of the alternative complement pathway in the 
pathogenesis of aHUS and provide support for the use of complement inhibition 
therapies to prevent or reduce tissue damage caused by dysregulated complement 
activation.
3INTRODUCTION
Hemolytic uremic syndrome (HUS, MIM 235400) is characterized by 
thrombocytopenia, Coomb’s test negative microangiopathic haemolytic anemia and 
acute renal failure (1). The typical form of HUS follows a diarrhoeal prodrome and is 
frequently associated with 0157:H7 E.coli infections (2). However, five to ten percent 
of HUS patients lack a particular relationship with infection and have the poorest long-
term prognosis (1). This atypical form of disease (aHUS) usually occurs in adults and in 
very young children and is associated with mutations or polymorphisms in the genes 
encoding the complement regulators factor H (CFH) (3-8), membrane cofactor protein 
(MCP) (9, 10), and factor I (IF) (11, 12).
The molecular mechanisms underlying aHUS are only now beginning to be understood. 
In contrast to patients with classical complement deficiencies, aHUS patients present 
relatively normal complement levels and activities in plasma (5). Crucially, functional 
analysis of several CFH, MCP and IF aHUS-associated mutations has demonstrated 
that they affect primarily the control of complement activation on cellular surfaces, 
while complement regulation in plasma is not greatly affected (4, 7, 10, 13). These 
findings have led to the hypothesis that aHUS results from a defective protection of host 
cells within the context of a “normal” complement function in fluid phase (7, 14). 
Under this perspective, a situation that triggers complement activation in the 
microvasculature will not be properly controlled, and the amplification of the initial 
damage will result in tissue destruction. 
Despite these advances in our understanding of the molecular basis of aHUS, no genetic 
defect has yet been found in two-thirds of aHUS patients, and incomplete penetrance of 
the disease in individuals carrying factor H, MCP or factor I mutations is relatively 
frequent, suggesting the existence of additional genetic factors that predispose to aHUS. 
4To provide further insights into the genetic factors predisposing to aHUS we have 
examined the hypothesis that genetic variants of complement activators, resulting in 
excessive activation of the complement system, are also aHUS risk factors. Like 
mutations in the complement regulators, genetic variations in complement activators 
have the potential to disrupt the balance between activation and regulation, 
dysregulating the complement system and predisposing to pathology when the 
complement system undergoes activation. 
Here we describe mutations in the gene encoding the complement activator factor B 
(BF) associated with aHUS. We report their functional characterization and demonstrate 
that they are gain-of-function mutations. These data offer a complementary view to the 
previously found loss-of-function mutations in complement regulators and definitively 
establish the critical role of the complement alternative pathway in the pathogenesis of 
HUS. In addition, we analyze the issue of incomplete penetrance of disease in BF
mutation carriers and show that, in a large multiple-affected Spanish HUS pedigree, the 
concurrence of an enhanced activation of the alternative pathway of complement with 
an impaired protection of host surfaces likely results in unrestricted activation of the 
alternative pathway at the cellular surfaces and triggers the development of aHUS. 
5PATIENTS, MATERIALS AND METHODS
Patients
This study includes a total of 74 aHUS patients selected on the basis of a clinical history 
of HUS with non-diarrhoea-associated origin. Of special relevance for this study are 
patients H55P, H55, H85 and H112, all members of a large multiple-affected Spanish 
pedigree, referred to as family PER, and H21, the propositus in family BRA. H55P is a 
male who presented aged 48 with HUS. Prolonged treatment with plasmapheresis failed 
to recover his renal function. He had no recurrences and has been on hemodialysis since 
then. H55, the daughter of H55P, presented in 1994, aged 23, two years after her first 
pregnancy, with the diagnosis of HUS. She was treated with plasma infusions, 
plasmapheresis and haemodialysis and showed improvement of renal function, but after 
four recurrences, she completely lost renal function in 2005 and is currently on 
peritoneal dialysis. H85, the nephew of H55P, presented with HUS in 1978, aged 2, 
following an upper respiratory tract infection. He improved after haemodialysis 
treatment and multiple blood transfusions and currently shows a moderate renal 
insufficiency. H112, the daughter of H85, presented aged 4 months with HUS with mild 
neurological signs in 2006, following an upper respiratory tract infection. She improved 
with plasma infusions which allowed her to stop haemodialysis. H21 is a boy who 
presented with HUS at 4 months in 2000 following a M. morganii respiratory tract 
infection. An initial recovery of renal function was followed by several recurrences that 
ended in complete lost of renal function two years after the first episode. Several 
neurological crises and persistent and severe hypertension made necessary bilateral 
nephrectomy at the age of 4. 
All protocols included in these studies have been approved by national and/or local 
institutional review boards, and all subjects gave their informed consent. 
6Complement analyses 
C3, C4, factor H and factor I levels were measured in serum or plasma samples as 
previously described (5, 15, 16). Factor B plasma levels were determined by a sandwich 
ELISA method using a polyclonal goat anti-human factor B antibody (NSC) as the 
capture antibody and a monoclonal mouse anti-human factor B as the detection 
antibody. To assess complement function and regulation we used the standard 
hemolytic assays CH50 and AP50 and a factor H-dependent hemolytic assay (13). 
Expression levels of the membrane regulators MCP and DAF in PBLs were determined 
by flow cytometry as previously described (17). 
Genotyping
Patients and their relatives were screened for mutations and polymorphisms in CFH,
MCP, IF and BF genes. DNA from these individuals was extracted from PBLs or from 
buccal mucosa cells collected with cheek brushes (MasterAmp buccal swab brush, 
Epicentre Technologies) using standard procedures. Each exon of the CFH, MCP and
IF genes was amplified from genomic DNA of patients using specific primers derived 
from the 5’ and 3’ intronic sequences as previously described (5, 10, 11). All BF exons 
were amplified from genomic DNA in three amplicons of 1800, 2500 and 2000 bp, 
respectively using three pairs of primers: 5`-CCA AGC CAG GAC ACA CCA TC-3` 
and 5`-TCT TCC GCT TCT GTT GTT CC-3`, 5`-TCA TGT ACG ACA CCC TCA A-
3` and 5`-AGC TCT CGT GTC CCT TTG AA-3`, 5`-ATG AAA GCC AGT CTC 
TGA-3` and 5`-CCTGTCCAGCAGGAAACC-3`. Several primers were used for 
sequencing the BF amplicons: 5`-GTT TCT CAG TGA CAT GGT CTC C-3`, 5`-TAT 
AGT GTT ACA AGT GGA CTT AAG G-3`, 5`-CTC AAC TTG CTC ACC CTG C-3`, 
5`- CAG ACT ATC AGG TGA GAG CGT C-3`, 5`- 
ACTAGCCACATGCATTGAGCT-3`, 5´- CTGATTCCTTTAGGTCAGCTAAG-3` 
7and also for the generation of the amplicons. Automatic sequencing was performed in 
an ABI 3730 sequencer using a dye terminator cycle sequencing kit (Applied 
Biosystems, NJ). Genotyping of HUS-associated CFH and MCP SNPs was performed 
by resequencing or by allelic discrimination using TaqMan probes (Applied 
Biosystems; Foster City, CA). 
Factor B purification 
Factor B from patients and controls was purified in one chromatographic step as 
follows. Two to five ml of plasma-EDTA were directly applied to a Sepharose column 
coated with the JC1 mouse monoclonal anti-human factor B antibody and previously 
equilibrated with Tris-HCl (20 mM pH 7.4) containing NaCl (50 mM). After extensive 
washes with equilibration, acetate (0.1 M, p H4, containing NaCl 500 mM) and borate 
(0.1 M, pH 8, containing NaCl 500 mM) buffers, the proteins bound to the column were 
eluted with 1 ml of glycine 100 mM pH 2.5 followed by equilibration buffer. 20 μl of 
Tris-HCl 2M pH 8 were added to the 500 μl eluted fractions to equilibrate glycine pH. 
Those fractions containing factor B were pooled and dialysed against Hepes 10 mM pH 
7.4 containing NaCl 50 mM.  
PAGE and Immunoblotting 
PAGE in the presence of SDS was performed using the buffer system described by 
Laemmli (1970). Samples were reduced at 100ºC for 5 min in the presence of 700 μM
mercaptoethanol (Sigma). Proteins were transferred onto nitrocellulose membranes and 
factor B revealed by using rabbit anti-factor B polyclonal antibody.
8SPR analysis of convertase formation 
Interactions of factor B with C3b were analysed on a BIAcore 3000 (BIAcore AB, 
Uppsala, Sweden) at 25°C. C3b was deposited on the surface of a CM5 chip as 
described previously (18). In brief, human C3.  factor B and factor D (Complement 
Technology Inc, Tyler, Tx) were flowed to seed the chip surface with small amounts of 
C3bBb; C3 was then flowed to densely coat the chip with  C3b coupled via the thioester 
to hydroxy groups on the carboxy-methyl dextran surface. Covalent coupling of C3b to 
the surface therefore occurred in the ‘native’ conformation. The surface was stabilised 
by a short injection of 50mM diethylamine, pH 11. Factor B preparations to be tested 
were purified by affinity chromatography from plasma of HUS patients (H21 and 
H55P) or a control subject and quantified by ELISA as described above. These factor B 
proteins (37μg/ml) were then flowed over the C3b surface at 20μl/min in HBS/Mg 
(10mM Hepes pH7.4, 50mM NaCl, 1mM MgCl2) with or without 2μg/ml factor D. 
Interactions were monitored and analysed using BIAcore BIAevaluation software, data 
from a blank reference cell were subtracted to account for any changes in refractive 
index of solutions flowing across the chip surface.  
Plate assay for AP convertase decay 
Assays were carried out essentially as described previously (18, 19). ELISA plates 
(MediSorp, Nunc, Roskilde, Denmark) were coated for 1 hour at 37°C with 3μg/ml 
C3b. C3b was prepared as described previously (18); coating of the plate with either 
C3b monomer or dimer (potential to form C5 convertase) did not alter assay results, 
hence all assays were performed with C3b monomer. After coating, plates were washed 
with VBS/Ni2+ (2.5mM sodium barbitone pH 7.4, 71mM NaCl, 1mM Ni2+, 0.1% Tween 
20) and blocked with VBS/Ni2+/1% BSA. Plates were washed in VBS/Ni2+ and 
9convertase was formed by incubating 0.5μg/ml factor B and 50ng/ml factor D in wells 
for 30 minutes at 37°C. Plates were washed and wells were then incubated with either 
buffer or known concentrations of a decay-accelerator, soluble recombinant DAF 
(sDAF; gift of Dr Susan M Lea, Biochemistry, Oxford University, UK) or soluble 
recombinant CR1 (sCR1, gift of T Cell Science, Needham, MA) for 20 minutes at 25°C. 
Plates were washed and remaining factor B was detected using polyclonal sheep anti-
factor B (The Binding Site, Birmingham, UK) followed by HRPO-conjugated anti-
sheep Ig. Colour was developed using OPD (Dako, Ely, UK). Background values were 
obtained by omitting factor B/factor D from some wells. Absorbance was measured at 
490nm and % convertase remaining was calculated as follows: % convertase remaining 
=100x(A490inh – A490Bgnd)/(A490buffer-A490bgnd). In some instances factor D was 
omitted from the incubations in order to assess formation of proenzyme and incubation 
with CD55 or sCR1 was omitted.
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RESULTS AND DISCUSSION 
Complement profiles in aHUS patients identifies subgroup with evidence of 
alternative pathway activation 
Our registry of aHUS patients includes 74 individuals who have been extensively 
studied with regard to complement profiles and genomic analyses of the complement 
regulatory genes CFH, MCP, IF and DAF. In concordance with other aHUS cohorts we 
found mutations in CFH, MCP or IF in approximately 30% of the aHUS patients 
(Figure 1a). No mutations were identified in the DAF gene.
Most patients in our HUS cohort present normal C3 and C4 levels (Figure 1b) and 
haemolytic complement activities (not shown). This is also in agreement with previous 
reports describing that, in general, HUS patients are not hypocomplementemic (5). We 
noticed, however, that some of the patients without mutations in the complement 
regulatory genes including patients H21, H49, H55P, H65 and H71, present evidence of 
alternative pathway activation. They show very low levels of C3 and normal or elevated 
levels of C4 (Figure 1b) and analysis of their plasma by western blot showed the 
presence of the activation product Ba (Figure 1c). Interestingly, H55P, belongs to a 
large multiple-affected aHUS Spanish kindred in which disease segregated with the 
MHC region in chromosome 6q24, a region that includes the complement factor B gene 
(BF) (20). 
Identification of BF mutations in patients with alternative pathway activation. 
The above observations pointed to BF as a new candidate gene predisposing to HUS 
and prompted us to search for mutations in BF in the group of patients showing 
evidence of alternative pathway activation. Two patients in this subgroup (H21; 
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pedigree BRA and H55P; pedigree PER) were found to carry missense mutations in 
heterozygosis in the BF gene. Genomic sequencing of BF in H55P revealed a 
heterozygous mutation (c.987C>G; F286L) in exon 6, encoding the von Willebrand 
type A domain of factor B. The F286L missense mutation segregates with the low levels 
of C3 that are present in different members of family PER and is inherited by all HUS-
affected members of this pedigree (Table 1, Figure 2a). Genomic sequencing of BF in 
H21 revealed another heterozygous mutation (c.1096A>G; K323E) in exon 7, also 
encoding a residue within the von Willebrand type A domain of factor B. K323E is a de
novo mutation that is not present in H21 parents (Figure 2b). Parental sample integrity 
in family BRA was confirmed by genotyping several markers in the RCA gene cluster 
in chromosome 1q32. Neither F286L nor K323E mutations were present in a control 
population including more than 100 normal individuals.  
Structure-function analyses identify BF gain-of-function mutations in aHUS. 
Factor B is a zymogen that carries the catalytic site of the complement alternative 
pathway convertase C3bBb. Upon interaction with C3b, factor B is cleaved by factor D 
into two fragments, Ba and Bb. Ba is released while Bb remains bound to C3b forming 
the C3bBb alternative pathway convertase, an active serine protease enzyme that 
cleaves additional C3 into C3b. The Bb fragment of factor B consists essentially of two 
protein domains: a von Willebrand factor type A domain and a serine protease (SP) 
domain (21). From structural studies, the factor B type A domain is a globular structure 
composed of several parallel β sheets surrounded by seven α?helices (22, 23). Site 
directed mutagenesis of factor B residues at the C3b-Bb interface in the factor B type A 
domain have identified a number of residues that are critical for the interaction between 
C3b and factor B and that influence the normal dissociation of C3b from Bb, whether it 
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is spontaneous or promoted by the complement regulatory proteins CFH, DAF or 
complement receptor 1 (CR1). In particular, the mutation D279G, in close proximity to 
the Mg2+ binding site within the factor B type A domain, caused resistance to decay 
acceleration mediated by all three regulators and also increased C3b binding affinity and 
C3bBb stability (24). Both of the BF mutations F286L and K323E identified here in the 
aHUS patients alter residues at the C3b-Bb interface in the type A domain of factor B in 
close proximity to the D279 (Figure 3). This finding led us to suspect that they have the 
potential for altering the stability of the C3bBb convertase and the activity of the 
alternative pathway. The mutation K323E changes a fully exposed residue with a 
positive charge to one with a negative charge. The mutation F286L influences Y319, 
another fully exposed residue, modifying the edge-to-face stacking interaction between 
F286 and Y319. Substituting F286 with leucine likely decreases mobility restrictions to 
Y319 at the C3b-Bb interface (Figure 3). 
To functionally characterize the effects of the K323E and F286L BF mutations we 
purified the factor B from the plasma of appropriate carriers and from normal controls 
and tested the purified factor B proteins for their capacity to form the C3 convertase and 
influence its decay, either spontaneous or promoted by complement regulatory proteins. 
Each protein was purified to homogeneity (Figure 4a). We have previously monitored 
formation and decay of the C3 convertase in real-time using surface plasmon resonance 
(SPR) (18). To assess the effects of mutations, factor B from controls or patients was 
flowed across a surface coated with C3b via its thioester group, with or without the 
factor B cleaving enzyme factor D (2μg/ml). Formation of C3bB (no factor D) was 
similar for control factor B and for K323E factor B isolated from patient H21; in 
marked contrast, F286L factor B isolated from patient H55P demonstrated a much more 
rapid and efficient formation of the C3bB complex (Figure 4b). In the presence of factor 
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D, the expected enhanced formation of the C3bBb complex was seen for control factor 
B and K323E factor B, while the kinetics of complex formation for F286L factor B 
were not further enhanced from that obtained in the absence of factor D (Figure 4c).
The above data show a clear functional consequence of the F286L mutation with 
enhanced formation of C3bB and no further enhancement of complex formation in the 
presence of factor D. However, the K323E factor B resembled normal factor B in the 
assay. To corroborate these findings a different assay system was used to investigate 
formation of the alternative C3-convertase by control and mutant factor B. C3b was 
immobilised on ELISA plates via the thioester and wells incubated with equal amounts 
of control and mutant factor B. Formation of C3bB was much enhanced with F286L 
factor B with two to three-fold more C3bB formed compared to control and K233E 
factor B, supporting the findings from SPR analysis (Fig 5a). When the C3bBb enzyme 
was formed in the presence of factor D the difference was much less apparent, with 
increased levels of complex formed by control factor B and K323E factor B (Fig 5b), 
supporting the SPR data. To further explore the effects of the K323E and F286L BF
mutations and to rule out the possibility that the presence of normal factor B in the 
patient samples, a consequence of heterozygosity, have masked subtle alterations caused 
by the K323E mutation, we then chose to analyse decay acceleration by DAF and sCR1. 
C3bBb enzymes formed on the plates were incubated with different amounts of DAF or 
sCR1 and the loss of Bb from the complex measured (Fig 5c, 5d). C3bBb formed from 
F286L factor B was less sensitive to decay by either sCR1 or CD55, demonstrating that 
the C3bBb complex made with this mutant is not only more efficiently generated but is 
also more resistant to decay by complement regulators. C3bBb complex formed by 
K323E factor B was sensitive to decay by sCR1 but reproducibly demonstrated a 
reduced sensitivity to decay by DAF, suggesting that C3bBb complex made with this 
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mutant will resist natural decay. It is important to emphasize that the functional 
differences described were observed despite the purified proteins from the patients 
comprise a mixture of normal and mutant factor B. Taken together, the data demonstrate 
that each of the mutant factor B proteins will produce increased alternative pathway 
activation. Formation of the C3bB complex by mutant F286L factor B is much 
enhanced, and decay acceleration by DAF and CR1 much reduced, producing more 
active enzyme in vivo. The functional consequences of the K323E mutation are more 
subtle and may be restricted to reduced susceptibility to decay, likely sufficient for 
increased enzyme activity in vivo. The mutations likely introduce conformational 
changes in the factor B type A domain that decrease the sensitivity of the C3bBb 
complex to decay by DAF and perhaps other complement regulators. It is not yet clear 
whether reduced decay is the result of an enhanced binding of Bb to C3b or decreased 
affinity for DAF. Nevertheless, these data demonstrate, for the first time, the existence 
of gain-of-function mutations in the BF gene and their association with HUS, 
illustrating the important contribution of the alternative pathway C3 convertase to the 
pathogenesis of HUS. 
Polymorphisms in the BF gene have recently been associated with age-related macular 
degeneration (AMD) (25), a disease that has previously been shown to strongly 
associate with polymorphisms in the CFH gene and where the macular pathology is 
driven by complement activation (26-29). Two BF polymorphisms were identified that 
were protective for AMD, one of which had previously been shown to reduce the 
haemolytic activity of factor B and the other, in the signal peptide, was suggested to 
modulate secretion of factor B. The observed protection in each case was ascribed to a 
reduced activity of the complement alternative pathway. This report provides timely 
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support for our suggestion that genetic changes that alter the function of factor B may 
influence pathology driven by alternative pathway activation.
Disease penetrance in carriers of BF mutations is modulated by other complement-
associated risk alleles. 
Within the HUS pedigree reported here, we have identified a total of 11 individuals 
carrying the F286L BF mutations, but only 7 of them have developed HUS thus far and 
the majority of the healthy carriers are old enough to assume that they are not at risk 
(Figure 2 and Table 2). Incomplete penetrance of the disease has also been reported for 
the aHUS-associated mutations in the CFH, MCP and IF genes (7, 9-11). Previously 
we, and others, have reported that two relatively frequent CFH and MCP SNPs 
haplotype blocks are strongly associated with aHUS (17, 30). We have proposed that 
concurrence of different susceptibility alleles greatly influences predisposition to aHUS 
and provides an explanation for the incomplete penetrance of aHUS in carriers of 
mutations in the complement regulator genes (17, 31). To investigate whether 
penetrance of the disease in BF mutations carriers is influenced by other aHUS genetic 
risk factors, we genotyped the CFH and MCP aHUS-associated SNP haplotype blocks 
and found that among carriers of the F286L mutation, all the HUS patients presented the 
MCPggaac risk allele, whereas among the healthy carriers (I-2, II-5, III-12 and IV-1) 
only the youngest, and probably still at risk, individual IV-1 harboured the HUS-
associated MCPggaac risk allele. Of note, the single affected individual with the K323E 
mutation also presented the MCPggaac risk allele. These data strongly suggest that the 
HUS phenotype associated with the BF gain-of-function mutations is modulated by 
common complement regulator gene variants, like the MCPggaac allele, associated with 
increased risk of developing HUS (17). 
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Complement dysregulation is the unifying event in aHUS patients. 
The efficiency of the complement system as an innate defence mechanism against 
microbial infections depends on a fine control that avoids the wasteful consumption of 
its components and restricts its activation to the surface of microorganisms, thus 
preventing non-specific damage to host tissues. Genetic and functional analyses of the 
complement regulatory proteins factor H, MCP and factor I have shown that this critical 
control of complement activation may be impaired in aHUS patients (4, 7, 10). The 
identification of gain-of-function mutations in BF associated with aHUS reinforces this 
view and illustrates that dysregulation of the complement system may also result from 
an abnormally increased activity of the alternative complement pathway activators. 
These findings identify other complement activators in the same pathway as BF, like C3
and CFP (encoding properdin), as potential candidate genes contributing to HUS 
susceptibility.
In conclusion, these data demonstrate the critical role of the alternative complement 
pathway in the pathogenesis of aHUS and expand our understanding of the genetic 
factors conferring predisposition to aHUS. Furthermore, they support the hypothesis 
that susceptibility to atypical HUS involves the concurrence of multiple factors (genetic 
and environmental) contributing to the dysregulation of the alternative complement 
pathway. This hypothesis provides an explanation for the incomplete penetrance of the 
disease in carriers of aHUS-associated mutations and may also be relevant in explaining 
the severe or fatal outcome of a small percentage of individuals with the more common 
diarrhoea-associated typical HUS. The findings provide further support for the use of 
complement inhibition therapies in aHUS and perhaps also in severe forms of typical 
HUS to prevent or reduce tissue damage caused by dysregulated complement activation.
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FOOTNOTES FOR THE FIGURES 
Figure 1. 
Activation of the alternative pathway in a subgroup of aHUS patients without 
mutations in the CFH, MCP and IF genes.
a) Distribution of CFH, MCP and IF mutations in the aHUS Spanish cohort.
b) C3 and C4 plasma levels in aHUS patients. C3 levels (0 to 200 mg/dL) are 
depicted in the x-axis with a vertical line indicating the lower C3 limit (77 
mg/dL) for the normal range of variation of the C3 levels in the Spanish 
population. C4 levels (0 to 60 mg/dL) are depicted in the y-axis with a 
horizontal line indicating the lower C4 limit (14 mg/dL) for the normal range of 
variation of the C4 levels in the Spanish population. The area shadowed in grey 
includes patients who present low or very low C3, but normal C4 levels 
indicating activation through the alternative pathway. Patients with detected 
mutations in CFH, MCP and IF are shown with filled circles and those without 
mutations with empty circles. C3 and C4 values are mean values in at least three 
bleedings at different times. 
c) Western blot of factor B with a goat polyclonal antibody of EDTA plasmas from 
H65, H21 and H55P HUS patients and EDTA-plasmas from 4 controls (N1 to 
N4). The presence of the activation Ba fragment of factor B is indicated. 
Figure 2.
Mutations in the BF gene in two aHUS pedigrees. 
Pedigrees of families PER (a) and BRA (b) are described. Individuals are identified by 
numbers within each generation (in Roman numbers). Affected individuals are indicated 
with solid symbols. Deceased individuals are crossed. Carriers of BF mutations are 
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indicated by an asterisk. For each BF mutation, the chromatogram corresponding to the 
DNA sequence surrounding the mutated nucleotide in BF is shown for the appropriate 
HUS patient and for a control sample. The corresponding amino acid sequences for the 
wild type and the mutated alleles are shown. The amino acid numbering is referred to 
the translation start site (Met +1) and the nucleotide nomenclature is referred to the 
transcription start site described in (32). 
Figure 3.
Structural implications for the HUS-associated BF mutations. 
Diagram of the von Willebrand type A domain of factor B. The positions of the residues 
Phe286 and Tyr323 that are mutated in the HUS patients are indicated. The position of 
the Mg2+ ion and that of the Asp279 and Tyr319 are also indicated. Notice the edge-to-
face stacking of F286 and Tyr319 residues. Numbering of residues is referred to the 
initial methionine and therefore includes the sequence of the N-terminal signal peptide. 
Residue Asp279 was described previously as Asp254 by (19). 
Figure 4.
SPR analysis of factor B purified from controls and carriers of HUS-associated BF 
mutations.
a) Coomassie and western blot illustrating the purification of factor B from patient 
and control EDTA plasmas and the absence of activation factor B fragments in 
all preparations. 
b) Formation of C3bB complexes. Control factor B (fBWT, dotted line) and factor B 
purified from H21 (fBK323E grey line) formed similar levels of the proenzyme 
whereas factor B purified from H55 (fBF286L solid line) formed C3bB complexes 
much more rapidly and to a much higher level. 
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c) Formation of C3bBb complexes. fBWT (dotted line) and fBK323E (grey line) 
formed similar levels of active enzyme and those were increased compared to 
the levels of proenzyme (4b). fBF286L (solid line) formed high and similar levels 
of complexes with C3b in the absence or presence of factor D.
Figure 5.
Convertase formation and decay monitored by plate assay.
a) Microtitre plates were coated with C3b. Wells were subsequently incubated with 
differing amounts of factor B purified from control (WT) or patients H55 
(F286L) and H21 (K323E). Bound factor B was detected as described in 
Methods and expressed relative to C3bB formation by factor B F286L as 100%. 
b) C3b-coated wells were incubated with factor B (0.5μg/ml) and factor D 
(50ng/ml), plates were incubated in buffer for 20 minutes and bound Bb was 
detected as described in Methods. Results are expressed relative to C3bBb 
formation by factor B F286L as 100% 
c) and d) Decay by sDAF or sCR1. Wells were incubated as in (b) and different 
amounts of sDAF (c) or sCR1 (d) were added. C3bBb complexes were then 
subjected to 20 minutes decay by soluble regulator. The experiments shown are 
representative of three different experiments. Each point was measured in 
quadruplicate and error bars represent standard errors of these replicates. 
1TABLE 1. Complement profiles in members of families PER and BRA.  
Status
C31, 2
(77–210mg/dL) 
C42
(14-47mg/dL) 
Factor H3
(12-56mg/dL) 
Factor B3
(7.5-28mg/dL) 
Factor I3
(75-115 %) 
MCP4
(91-109%) 
I-2 Healthy 68 24 38 15 n.a. n.a.
II-5 Healthy 75 25 37 16 n.a. n.a.
II-7 (H55P) Affected 46 29 36 17 118 100 
II-10 Healthy 122 28 35 22 n.a. 121
II-11 Healthy 123 28 38 26 n.a. n.a.
III-7 (H55) Affected 91 36 32 16 104 110 
III-12 Healthy 67 16 42 13 n.a. n.a. 
III-13 (H 85) Affected 60 19 23 12 98 118 
III-14 Healthy 117 21 33 12 n.a. 98
IV-1 Healthy 134 17 27 15 n.a. n.a.
P
E
R
IV-2 (H 112) Affected 65 25 24 22 95 66 
I-1 Healthy 102 28 38 11 84 n.a.
I-2 Healthy 89 28 28 12 85 n.a.
B
R
A
II-1 (H21) Affected 23 32 26 21 103 84 
1) Normal range of variation in controls for each variable is shown between brackets. 
2) C3 and C4 were determined by nephelometry. 
3) Factor H, Factor B and Factor I plasma levels were determined by ELISA. Factor I levels are referred to a reference serum; each value 
corresponds to the mean of three independent determinations.  
4) Levels of MCP in PBLs (MFI, mean fluorescence intensity) were determined by flow cytometry and referred to a series of control 
samples drawn and analysed the same day. The average MFI value for the control samples was set to 100%. Range of variation for all 
control samples (n=17) was within 10% of the average value (91 to 109%). 
5) Pedigree codes as in Figure 2. BF mutation carriers are labelled with black triangles. HUS patients are identified by their code in 
parenthesis. 
6) n.a.: not available. 
1TABLE 2. aHUS-associated CFH and MCP SNPs haplotype blocks and disease status in carriers of BF mutations. 
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